Blog Tool

Sensydia Awarded Second Phase of $3M NIH Grant Award to Demonstrate Clinical Utility of Cardiac Performance System (CPS™)

The NIH has activated Phase II funding of Sensydia’s Fast-Track STTR grant to support real-world clinical utility studies of the Cardiac Performance System (CPS™). This non-dilutive funding marks a key milestone as the company continues to validate CPS for patients with heart failure and pulmonary hypertension.

Admin

Jun 92 min read

Rusty Page appointed President and Chief Operating Officer of Sensydia.

Sensydia Appoints Rusty Page as President and Chief Operating Officer to Support Growth and Commercialization of the Cardiac Performance System (CPS™)

Industry veteran brings over 20 years of medical device leadership to guide operations, quality, and infrastructure as Sensydia advances toward FDA submission and commercialization of the Cardiac Performance System (CPS™).

Admin

May 62 min read

Sensydia’s Cardiac Performance System (CPS™) is designed for fast, safe, and non-invasive cardiac performance assessment that can be performed almost anywhere, avoiding the need to visit a catheterization lab. Source: Sensydia.

Sensydia Announces First Patient Enrolled in Pivotal Study of Non-Invasive Cardiac Performance System (CPS™)

Sensydia has enrolled the first patient in its pivotal clinical study evaluating the Cardiac Performance System (CPS™), a non-invasive solution for hemodynamic assessment. This milestone advances CPS™ toward FDA submission and supports Sensydia’s mission to transform the management of heart failure and other cardiac conditions through faster, safer diagnostics.

Admin

Apr 282 min read

Clinical data presented at ACC 2025 shows Sensydia CPS™ provides accurate assessment of mean pulmonary artery pressure non-invasively

Completion of this 50-subject study is a key milestone on the path to delivering the first device for non-invasive and accurate...

Admin

Mar 293 min read